These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21876341)

  • 1. Characterization of patient-reported outcomes in moderate to severe psoriasis.
    Krenzer S; Radtke M; Schmitt-Rau K; Augustin M
    Dermatology; 2011; 223(1):80-6. PubMed ID: 21876341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.
    Schäfer I; Hacker J; Rustenbach SJ; Radtke M; Franzke N; Augustin M
    Eur J Dermatol; 2010; 20(1):62-7. PubMed ID: 19822480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
    Radtke MA; Schäfer I; Blome C; Augustin M
    Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
    Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
    Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
    J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.
    Augustin M; Reich K; Reich C; Purwins S; Jeff Rustenbach S; Schäfer I; Radtke M
    J Dtsch Dermatol Ges; 2008 Aug; 6(8):640-5. PubMed ID: 18801145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.
    Feuerhahn J; Blome C; Radtke M; Augustin M
    Arch Dermatol Res; 2012 Aug; 304(6):433-41. PubMed ID: 22722916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
    Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I; Stenberg B; Svensson A; Bergbrant IM
    Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis.
    Balato N; Megna M; Di Costanzo L; Balato A; Ayala F
    Br J Dermatol; 2013 Jan; 168(1):201-5. PubMed ID: 23240729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness-to-pay and quality of life in patients with vitiligo.
    Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
    Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
    Augustin M; Blome C; Paul C; Puig L; Luger T; Lambert J; Chimenti S; Girolomoni G; Kragballe K; Naessens D; Bergmans P; Smirnov P; Barker J; Reich K
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):294-303. PubMed ID: 27515070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.